Indian Generics Slash Semaglutide Prices by Up to 80% Undercutting Novo Nordisk
Novo Nordisk lost its semaglutide patent in India, enabling over 40 manufacturers to launch more than 50 generic weight-loss drugs and forcing prices down by up to 80%. Some generics retail for as little as $14 monthly, with Dr. Reddy’s version at $45, eroding Novo’s pricing power.
1. Patent Expiry Spurs Generic Entry
The expiration of Novo Nordisk’s semaglutide patent in India triggered the immediate launch of over 50 generic weight-loss formulations by more than 40 local manufacturers, driving prices down by up to 80% within days.
2. Leading Indian Manufacturers and Pricing
Companies such as Sun Pharma, Dr. Reddy’s, Zydus, Torrent, Glenmark, Alkem and Natco have introduced generic versions priced between INR 1,300 ($14) and INR 4,200 ($45) per monthly dose, undercutting Wegovy and Ozempic.
3. Impact on Novo Nordisk’s Market Share
The influx of low-cost generics threatens Novo’s revenue streams and pricing power in India’s large diabetic and obese population, potentially eroding market share and weighing on profit margins.
4. Global Pricing Benchmark Potential
Indian generics aim to export to Latin America, Canada and Turkey, setting a low-price benchmark that could pressure Novo Nordisk’s semaglutide economics as patents expire in other regions.